## Mechanism: 
- fully human IgG monoclonal IL-12 and IL-23 antagonist ➔ prevents binding of the p40 subunit (CD4 T cells and NK cells ) of IL-12 & IL-23 ➔ suppresses the formation of proinflammatory TH1 and TH17 cells 
## Indications: 
- adult patients with PsA, plaque psoriasis, and Crohn’s disease 
## Adverse Effects: 
- Upper respiratory tract infection and reversible posterior leukoencephalopathy syndrome. 
- Noted: 
	- discontinued ≥15 weeks before live vaccines are administered and can be resumed 2 weeks after